Novartis gets approval to sell Kymriah in Japan for $306,000

15 May 2019 - A Japanese government panel approved on Wednesday a price of 33.5 million yen ($305,800) for Novartis’ cancer ...

Read more →

Medicare proposes boosting payments for CAR-T cancer therapy

24 April 2019 - The U.S. government is proposing to increase payments for innovative CAR-T cancer therapies, the administrator of ...

Read more →

New genetic therapies in cancer treatment could impact benefits plans

12 April 2019 - In September 2018, Health Canada approved, for the first time, the use of a chimeric antigen ...

Read more →

FDA agrees to rolling review of Mesoblast's biologic licence application for its cell therapy in children with steroid-refractory acute graft versus host disease

16 April 2019 - Mesoblast announced today that the FDA has agreed that Mesoblast can submit on a rolling basis ...

Read more →

Federal Government takes first major step in adopting new wave of personalised medicine for Australian patients

16 April 2019 - Medicines Australia welcomes the Government’s investment in new technology with Kymriah (tisagenlecleucel) CAR-T (Chimeric Antigen Receptor ...

Read more →

Future in cancer treatment arrives for Australian children and young adults battling leukaemia

15 April 2019 - Hon Greg Hunt MP Minister for Health today announces availability of novel life-saving cancer treatment CAR-T ...

Read more →

EMA grants PRIME designation to Janssen’s investigational CAR-T therapy

4 April 2019 - Johnson & Johnson’s Janssen has announced the granting of a PRIME (PRIority MEdicines) designation for its ...

Read more →

Immunocore’s lead asset tebentafusp gains fast track designation for metastatic uveal melanoma

3 April 2019 - Immunocore today announces that the U.S. FDA has granted fast track designation for its development program, ...

Read more →

bluebird bio receives positive opinion from CHMP for Zynteglo (autologous CD34+ cells encoding βA-T87Q-globin gene) gene therapy for patients 12 years and older with transfusion-dependent β-thalassemia who do not have β0/β0 Genotype

29 March 2019 - First gene therapy recommended for approval in the EU for transfusion-dependent β-thalassemia. ...

Read more →

Highlights from CHMP 25-28 March 2019 meeting

29 March 2019 - EMA’s human medicines committee (CHMP) adopted recommendations for one new initial marketing authorisation and three extensions ...

Read more →

bluebird bio statement on European regulatory status of LentiGlobin

25 March 2019 - A third party press release was issued today stating that the EMA issued an approval for ...

Read more →

Melbourne's Peter MacCallum Cancer Centre to be home of 'the next great wave in treatment'

25 March 2019 - A new form of cancer treatment that uses cell therapy to attack the disease will become ...

Read more →

SMC says ‘no’ to Novartis’ Kymriah for adults with lymphoma

11 March 2019 - Adults with lymphoma will not be able to access Novartis’ CAR-T therapy Kymriah on the NHS ...

Read more →

Japan approves two gene treatments in bid to catch up

21 February 2019 - Potential revolutionary treatments have exorbitant price tags. ...

Read more →

Gilead receives approval in Canada for Yescarta (axicabtagene ciloleucel) CAR T therapy for adults with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy

19 February 2019 - Yescarta is a chimeric antigen receptor T-cell therapy that is custom-made for each patient from his or ...

Read more →